A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
SUMMARY OF PRINCIPAL RISK FACTORS This summary briefly states the principal risks and uncertainties facing our business that could affect our common stock, which are only a select portion of those risks. A more complete statement of those risks and uncertainties is set forth in the Section 1A “Risk Factors” of this report. This summary is qualified in its entirety by that more complete statement. You should carefully read the entire statement and “Risk Factors” when considering the risks and uncertainties as part of your evaluation of an investment in our common stock. •We will require substantial additional funding to achieve our goals. If we do not generate sufficient funding from our existing collaboration and any future collaborations, we will need to obtain additional funding to support our operations. A failure to obtain funding when needed could force us to delay, limit, reduce or terminate some or all of our product development efforts.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 67M | 65M | 68M | 79M | 86M | 97M |
| Net Income | -72M | -82M | -116M | -134M | -122M | -79M |
| EPS | $-3.21 | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 |
| Free Cash Flow | -18M | -32M | -97M | -112M | -87M | -71M |
| ROIC | -17.5% | -84.6% | -90.1% | -61.7% | -37.9% | -19.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.89 | 0.43 | 0.12 | 0.08 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -73M | -85M | -122M | -137M | -124M | -110M |
| Operating Margin | -109.1% | -130.7% | -179.9% | -173.2% | -143.7% | -112.9% |
| ROE | -56.5% | -84.6% | -90.1% | -61.7% | -37.9% | -19.8% |
| Shares Outstanding | 29M | 21M | 21M | 21M | 21M | 20M |
ENANTA PHARMACEUTICALS INC passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -25.1%.
ENANTA PHARMACEUTICALS INC (ENTA) has a 5-year average return on invested capital (ROIC) of -58.8%. This is below average and may indicate limited pricing power.
ENANTA PHARMACEUTICALS INC (ENTA) has a market capitalization of $414M. It is classified as a small-cap stock.
ENANTA PHARMACEUTICALS INC (ENTA) does not currently pay a regular dividend.
ENANTA PHARMACEUTICALS INC (ENTA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ENANTA PHARMACEUTICALS INC (ENTA) reported annual revenue of $65 million in its most recent fiscal year, based on SEC EDGAR filings.
ENANTA PHARMACEUTICALS INC (ENTA) has a net profit margin of -125.4%. The company is currently unprofitable.
ENANTA PHARMACEUTICALS INC (ENTA) generated $-32 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ENANTA PHARMACEUTICALS INC (ENTA) has a debt-to-equity ratio of 0.89. This indicates moderate leverage.
ENANTA PHARMACEUTICALS INC (ENTA) reported earnings per share (EPS) of $-3.84 in its most recent fiscal year.
ENANTA PHARMACEUTICALS INC (ENTA) has a return on equity (ROE) of -84.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for ENANTA PHARMACEUTICALS INC (ENTA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ENANTA PHARMACEUTICALS INC (ENTA) has a book value per share of $3.03, based on its most recent annual SEC filing.